← Leaderboards
Dmitri Sviridov
George Washington University
$5,414,716
Attributed
$13,148,503
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,148,503 · 6
By mechanism
R01$12,766,431 · 5
R21$382,072 · 1
Top collaborators
- Michael Ilya Bukrinsky27 shared
- Michael Leo Fitzgerald8 shared
- William R Tyor5 shared
Most similar at George Washington University
Same institution · by research overlap
- Raj M Lakshman$7,988,460
- Anne C Fitzpatrick$212,808
- David I Watkins$75,196,434
- Henry Hale$149,242
- Andrei Afanasev$1,040,478
Others in their field
Top investigators on “Pathogenesis”
- Jeffrey P Krischer · University Of South Florida$473,867,135
- Constance Ann Benson · University Of California, San Diego$309,631,408
- Daniel R Kuritzkes · Brigham And Women'S Hospital$212,627,101
- Richard K. Wilson · Washington University$203,917,615
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$198,007,440
- Carol Nesel · Westat$147,274,423
Research focus
PathogenesisHiv InfectionsCholesterol HomeostasisImpairmentMediatingMetabolicPlayLipid MetabolismCardiovascular DiseasesAtherosclerosisCellsAffectNef ProteinHigh RiskHiv-1Inflammatory ResponseAnti-Retroviral AgentsStructurePharmaceutical PreparationsIn VivoPreventBloodLipidsInfection
Grant awards (27)
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$744,154
R01 · FY2024 · NS
Lipid raft therapy â a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities$627,036
R01 · FY2024 · HL
Epigenetic mechanisms of HAND pathogenesis$382,072
R21 · FY2024 · NS
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$762,862
R01 · FY2023 · NS
Lipid raft therapy â a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities$634,030
R01 · FY2023 · HL
Supplement to R01 NS124477$34,154
R01 · FY2023 · NS
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$680,858
R01 · FY2022 · NS
Lipid raft therapy â a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities$640,876
R01 · FY2022 · HL
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$730,589
R01 · FY2021 · NS
Lipid raft therapy â a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities$693,497
R01 · FY2021 · HL
Metabolic complications of HIV disease caused by Nef released from HIV-infected cells$382,352
R01 · FY2019 · HL
Metabolic complications of HIV disease caused by Nef released from HIV-infected cells$390,491
R01 · FY2018 · HL
Metabolic complications of HIV disease caused by Nef released from HIV-infected cells$398,415
R01 · FY2017 · HL
Metabolic complications of HIV disease caused by Nef released from HIV-infected cells$420,750
R01 · FY2016 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$728,214
R01 · FY2015 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$727,875
R01 · FY2014 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$677,773
R01 · FY2013 · HL
Mechanisms of virus-induced impairment of reverse cholesterol transport$306,327
R01 · FY2013 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$716,126
R01 · FY2012 · HL
Mechanisms of virus-induced impairment of reverse cholesterol transport$323,796
R01 · FY2012 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$156,292
R01 · FY2012 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$124,801
R01 · FY2012 · HL
Mechanisms of virus-induced impairment of reverse cholesterol transport$325,761
R01 · FY2011 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$124,801
R01 · FY2011 · HL
HIV Disease and Impairement of High Density Lipoprotein Metabolism$748,717
R01 · FY2010 · HL
Mechanisms of virus-induced impairment of reverse cholesterol transport$324,914
R01 · FY2010 · HL
Mechanisms of virus-induced impairment of reverse cholesterol transport$340,970
R01 · FY2009 · HL